A phase Ib, open-label, multicenter study to investigate the pharmacokinetics, pharmacodynamics, and safety of tocilizumab following subcutaneous administration to patients with polyarticular-course juvenile idiopathic arthritis
Read time: 1 mins
Last updated:20th Jun 2013
The primary objective is to characterize the pharmacokinetics of subcutaneous tocilizumab (SC TCZ) in patients with pcJIA.
|Study start date||2013-06-20|